Hepion Pharmaceuticals Inc (HEPA)

[Fress]

Hepa targets are the $8:25-$8:50 range and then $16.00-$17.00 range I will sell incrementally at those 2 target area’s and then ride the rest free shares. I really believe this company can fetch a 50-100 billion market cap within 5 years. Nash competitors AKRO & MDGL have a 1.2 billion and 1.7 billion market cap with safety records no where near as safe as HEPA molecule CRV431 and the top line doses on low mg 75mg are inline with MDGL phase 3 Hepas larger milligrams 150 and 225mg should blow MDGL out of the water. Remember Foster the CEO said CRV431 was so safe that you could put it in the drinking water. On a disease like NASH with no FDA approved drugs. The FDA really would first and foremost will be looking for a drug that is safe. CRV431 is that drug that has the potential to treat a wide array of indications along with NASH including other cancers, diabetes, Alzheimer’s. The imperative take away is Hobbs leaving a high level executive position for 17 years at Novo nordisk a 190 billion dollar company. He ain’t coming to be the CMO.Chief medical officer to a micro cap biotech company like HEPA unless there was proof of that the molecules results are PROFOUND.
ATOS 3 month chart looks similar to where HEPA is today. ATOS moved from 1.45 to high 9.00s in a hundred days. Be patient accumulate Hepa at these levels! IMO.

$HEPA